AAVB-081

BIOLOGICAL2 trials

Sponsors

Aavantgarde Bio S.r.l., AAVantgarde Bio Srl

Conditions

Usher Syndrome Type 1B (USH1B) Retinitis PigmenotsaUsher Syndrome, Type 1B

Phase 1

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

RecruitingNCT06591793

AAVantgarde Bio SrlUsher Syndrome, Type 1B

Start: 2024-07-02End: 2029-07-31Target: 15Updated: 2025-05-02

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Participants with Usher Syndrome Type 1B (USH1B) Retinitis Pigmentosa

Active, not recruitingCTIS2024-518489-29-00

Aavantgarde Bio S.r.l.Usher Syndrome Type 1B (USH1B) Retinitis Pigmenotsa

Start: 2024-07-01Target: 9Updated: 2025-06-05